AT219610B - Process for the preparation of new iminodibenzyl derivatives and their salts - Google Patents
Process for the preparation of new iminodibenzyl derivatives and their saltsInfo
- Publication number
- AT219610B AT219610B AT151961A AT151961A AT219610B AT 219610 B AT219610 B AT 219610B AT 151961 A AT151961 A AT 151961A AT 151961 A AT151961 A AT 151961A AT 219610 B AT219610 B AT 219610B
- Authority
- AT
- Austria
- Prior art keywords
- salts
- acid
- preparation
- new
- general formula
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 5
- 238000000034 method Methods 0.000 title description 4
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical class C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 8
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 7
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 229910052987 metal hydride Inorganic materials 0.000 claims description 2
- 150000004681 metal hydrides Chemical class 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001339 alkali metal compounds Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
Landscapes
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung von neuen Iminodibenzylderivaten und deren Salzen
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung neuer N-heterocyclischer Verbindungen mit wertvollen pharmakologischen Eigenschaften, sowie der zugehörigen Zwischenprodukte.
Es wurde gefunden, dass man Verbindungen mit wertvollen pharmakologischen Eigenschaften, die der allgemeinen Formel I entsprechen,
EMI1.1
worin R Wasserstoff, einen niederen Alkylrest oder einen Aralkylrest, X einen geradkettigen oder verzweigten Alkylenrest mit 2 - 6 Kohlenstoffatomen, und Am eine niedere Alkylamino- oder Dialkylamino- gruppe bedeuten, wobei einer der beiden Alkylreste einer Dialkylaminogruppe Am direkt (1) mit dem AlkylrestXoder beide Alkylreste unter sich direkt (2) oder über ein Sauerstoffatom (3), eine niedere Alkylimino- (4), Hydroxyalkylimino- (5) oder Alkanoyloxyalkyliminogruppe (6) verbunden sein können bzw. deren Salze mit anorganischen oder organischen Säuren herstellen kann, indem man Verbindungen der allgemeinen Formel :
EMI1.2
worin X'und Am"'Reste bedeuten, welche mit den weiter oben definierten Resten X bzw. Am bis auf mindestens eine an ein Stickstoffatom gebundene Carbonylgruppe, die in mindestens einem der Reste X' und Am"'an die Stelle einer Methylengruppe tritt, übereinstimmen, und R'die unter der allgemeinen Formel 1I1 angegebene Bedeutung hat, mit einem Alkalimetall-Erdmetall-Hydrid, insbesondere mit Lithiumaluminiumhydrid reduziert und nötigenfalls das Reduktionsprodukt, je nach der Bedeutung von R', durch vorzugsweise saure Hydrolyse oder durch Hydrogenolyse in eine Verbindung der oben definierten allgemeinen Formel I umwandelt.
Die folgenden Formeln sind spezielle Beispiele zur Erläuterung der oben erwähnten sechs Bindungsmöglichkeiten in der Gruppierung X - Am
<Desc/Clms Page number 2>
EMI2.1
EMI2.2
EMI2.3
EMI2.4
<Desc/Clms Page number 3>
EMI3.1
derworin R'und X die oben angegebene Bedeutung haben mit Alkalimetallverbindungen von niederen Alkancarbonsäureamiden, Alkancarbonsäure-N-alyl-amiden, Dialkancarbonsäureimiden, 6-Valerolactam, e-Caprolactam, Succinimid oder Glutarimid,
oder gegebenenfalls auch durch Acylierung von substituierten 5-Aminoalkyl-oder 5-Alkylaminoalkyl-iminodibenzylen der allgemeinen Formel
EMI3.2
worin Am" die Aminogruppe oder eine niedere Alkylaminogruppe bedeutet und X und R'die weiter oben angegebene Bedeutung haben.
Die erfindungsgemäss herstellbaren Verbindungen besitzen insbesondere antiallergische, sedative, serotoninantagonistische, antipyretische und thymoleptische Wirksamkeit bei nur geringen vegetativen
Nebenwirkungen. Sie eignen sich beispielsweise zur Behandlung von gewissen Formen von Geisteskrankheiten, insbesondere Gemütsdepressionen, wobei sie peroral oder in Form von wässerigen Lösungen nichttoxischer Salze auch parenteral angewendet werden können. Teilweise eignen sie sich auch als Zwischenprodukte für die Herstellung weiterer Stoffe mit ähnlichen Eigenschaften.
Mit anorganischen oder organischen Säuren, wie Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, Äthandisulfonsäure, Essigsäure, Bernsteinsäure, Fumarsäure, Maleinsäure, Äpfelsäure, Weinsäure, Citronensäure, Benzoesäure und Phthalsäure bilden die erfindungsgemäss herstellbaren Verbindungen der allgemeinen Formel I Salze, welche zum Teil wasserlöslich sind.
Die nachfolgenden Beispiele sollen die erfindungsgemässe Herstellung von Verbindungen der allgemeinen Formel I näher erläutern, stellen jedoch keineswegs die einzigen Ausführungsmöglichkeiten der- selbendar. IndenBeispielen bedeuten Teile, sofern nichts anderes vermerkt ist. Gewichtsteile ; diese verhalten sich zu Volumteilen wie g zu cms. Die Temperaturen sind in Celsiusgraden angegeben.
Beispiel 1 : 4, 26Teile2-Benzyloxy-5-piperidino-caxbonylmethyl-iminodibenzylin100Volurfitei- len Tetrahydrofuran werden unter Rühren zu einer Suspension von 1 Teil Lithiumaluminiumhydrid in 100 Volumteilen Diäthyläther zugetropft, das Reaktionsgemisch anschliessend 5 Stunden zum Sieden unter Rückfluss erwärmt, dann auf -100 abgekühlt und mit Wasser zersetzt. Die ätherische Phase wird dreimal mit 2-n. Salzsäure extrahiert, die vereinigten salzsauren Extrakte werden mit konz. Ammoniaklösung basisch gestellt und die erhaltene Suspension mit Äther extrahiert. Der Ätherextrakt wird über Natriumsulfat getrocknet und eingedampft, wobei das rohe 3-Benzyloxy-5- (ss-piperidino-äthyl)-iminodibenzyl zurückbleibt.
Dieses wird mittels äthanolischer Chlorwasserstofflösung in das Hydrochlorid übergeführt und letzteres aus Methanol/Aceton umkristallisiert. Smp. 208-2090 nach Umwandlung in feine Nadeln oberhalb 1850.
Beispiel 2 : 4, 0 Teile 2, Benzyloxy-5- [y- (N-formyl-methylamino)-propylJ-Iminodibenzyl in 100 Volumteilen Diäthyläther werden unter Rühren zu einer Suspension von 1 Teil Lithiumaluminlumhy- drid in 50 Volumteilen Diäthyläther zugetropft und das Reaktionsgemisch 5 Stunden zum Sieden unter Rückfluss erwärmt. Nach dem Erkalten wird das überschüssige Lithiumaluminiumhydrid mit 3 Volumteilen Me7 thanol in 15 Teilen Äther zersetzt, das Ganze mit Wasser versetzt, die ätherische Phase abgetrennt und dreimal mit 2-n. Salzsäure extrahiert. Die vereinigten Extrakte werden mit konz. Natronlauge alkalisch
<Desc/Clms Page number 4>
gestellt. Die ausgeschiedene Base wird in Äther aufgenommen, getrocknet und eingedampft.
Der Rückstand wird im Hochvakuum destilliert, das 2-Benzyloxy-5- (y-dimethylamino-propyl)-iminodibenzyl geht unter 0, 002 mm Druck bei 212-215 über.
EMI4.1
(y-dimethylamino-propyl)-iminodibenzyl Smp. 132PATENTANSPRUCH : Verfahren zur Herstellung von neuen Iminodibenzylderivaten der allgemeinen Formel
EMI4.2
worin R Wasserstoff, einen niederen Alkyliest oder einen Aralkylrest, X einen geradkettigen oder verzweig- ten Alkylenrest mit 2 - 6 Kohlenstoffatomen. und Am eine niedere Alkylamino-oder Dialkylaminogrup-
EMI4.3
ganischen oder organischen Säuren, dadurch gekennzeichnet, dass man eine Verbindung der allgemeinen Formel
EMI4.4
EMI4.5
**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.
<Desc / Clms Page number 1>
Process for the preparation of new iminodibenzyl derivatives and their salts
The present invention relates to a process for the preparation of new N-heterocyclic compounds with valuable pharmacological properties, as well as the associated intermediate products.
It has been found that compounds with valuable pharmacological properties which correspond to the general formula I
EMI1.1
where R is hydrogen, a lower alkyl radical or an aralkyl radical, X is a straight-chain or branched alkylene radical with 2 - 6 carbon atoms, and Am is a lower alkylamino or dialkylamino group, one of the two alkyl radicals of a dialkylamino group Am being directly (1) with the alkyl radical Xor both alkyl radicals can be linked directly (2) or via an oxygen atom (3), a lower alkylimino (4), hydroxyalkylimino (5) or alkanoyloxyalkylimino group (6) or can produce their salts with inorganic or organic acids by one compounds of the general formula:
EMI1.2
where X 'and Am "' denote radicals which, with the radicals X and Am defined above, except for at least one carbonyl group bonded to a nitrogen atom which takes the place of a methylene group in at least one of the radicals X 'and Am"', match, and R 'has the meaning given under the general formula 11, reduced with an alkali metal-earth metal hydride, in particular with lithium aluminum hydride and, if necessary, the reduction product, depending on the meaning of R', preferably by acid hydrolysis or by hydrogenolysis into a compound of the general formula I defined above.
The following formulas are specific examples to illustrate the above-mentioned six bonding possibilities in the grouping X - Am
<Desc / Clms Page number 2>
EMI2.1
EMI2.2
EMI2.3
EMI2.4
<Desc / Clms Page number 3>
EMI3.1
derworin R 'and X have the meaning given above with alkali metal compounds of lower alkanecarboxamides, alkanecarboxylic acid N-alyl amides, dialkanecarboximides, 6-valerolactam, e-caprolactam, succinimide or glutarimide,
or optionally also by acylation of substituted 5-aminoalkyl- or 5-alkylaminoalkyl-iminodibenzyls of the general formula
EMI3.2
wherein Am "denotes the amino group or a lower alkylamino group and X and R 'have the meaning given above.
The compounds which can be prepared according to the invention have, in particular, antiallergic, sedative, serotonin-antagonistic, antipyretic and thymoleptic activity with only low vegetative activity
Side effects. They are suitable, for example, for the treatment of certain forms of mental illness, in particular mood depression, and they can also be used orally or parenterally in the form of aqueous solutions of non-toxic salts. Some of them are also suitable as intermediate products for the manufacture of other substances with similar properties.
With inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanedisulfonic acid, acetic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, citric acid, benzoic acid and phthalic acid, the compounds of the general formula I which can be prepared according to the invention form salts, some of which are water soluble.
The following examples are intended to explain the preparation according to the invention of compounds of the general formula I in more detail, but by no means represent the only possible embodiments of the same. In the examples, parts mean parts unless otherwise noted. Parts by weight; these are related to parts of volume as g to cms. The temperatures are given in degrees Celsius.
Example 1: 4.26 parts of 2-benzyloxy-5-piperidino-caxbonylmethyl-iminodibenzylin100 volumetric parts of tetrahydrofuran are added dropwise with stirring to a suspension of 1 part of lithium aluminum hydride in 100 parts by volume of diethyl ether, and the reaction mixture is then heated to reflux for 5 hours cooled and decomposed with water. The ethereal phase is repeated three times with 2-n. Hydrochloric acid extracted, the combined hydrochloric acid extracts with conc. Ammonia solution made basic and the resulting suspension extracted with ether. The ether extract is dried over sodium sulfate and evaporated, the crude 3-benzyloxy-5- (ss-piperidino-ethyl) -iminodibenzyl remaining.
This is converted into the hydrochloride by means of an ethanolic hydrogen chloride solution and the latter is recrystallized from methanol / acetone. M.p. 208-2090 after conversion into fine needles above 1850.
Example 2: 4.0 parts of 2, benzyloxy-5- [y- (N-formyl-methylamino) -propylJ-iminodibenzyl in 100 parts by volume of diethyl ether are added dropwise with stirring to a suspension of 1 part of lithium aluminum hydride in 50 parts by volume of diethyl ether and that The reaction mixture was heated to reflux for 5 hours. After cooling, the excess lithium aluminum hydride is decomposed with 3 parts by volume of methanol in 15 parts of ether, water is added to the whole, the ethereal phase is separated off and 2-n. Hydrochloric acid extracted. The combined extracts are with conc. Caustic soda alkaline
<Desc / Clms Page number 4>
posed. The precipitated base is taken up in ether, dried and evaporated.
The residue is distilled in a high vacuum, the 2-benzyloxy-5- (γ-dimethylamino-propyl) -iminodibenzyl passes over under 0.002 mm pressure at 212-215.
EMI4.1
(y-dimethylamino-propyl) -iminodibenzyl mp. 132 PATENT CLAIM: Process for the preparation of new iminodibenzyl derivatives of the general formula
EMI4.2
where R is hydrogen, a lower alkyl ester or an aralkyl radical, X is a straight-chain or branched alkylene radical having 2 to 6 carbon atoms. and Am is a lower alkylamino or dialkylamino group
EMI4.3
ganischen or organic acids, characterized in that one is a compound of the general formula
EMI4.4
EMI4.5
** WARNING ** End of DESC field may overlap beginning of CLMS **.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT151961A AT219610B (en) | 1960-05-27 | 1960-05-27 | Process for the preparation of new iminodibenzyl derivatives and their salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT151961A AT219610B (en) | 1960-05-27 | 1960-05-27 | Process for the preparation of new iminodibenzyl derivatives and their salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT219610B true AT219610B (en) | 1962-02-12 |
Family
ID=3515380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT151961A AT219610B (en) | 1960-05-27 | 1960-05-27 | Process for the preparation of new iminodibenzyl derivatives and their salts |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT219610B (en) |
-
1960
- 1960-05-27 AT AT151961A patent/AT219610B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH629190A5 (en) | Process for the preparation of 1-(triarylalkyl)-4-phenylpiperidine derivatives | |
| AT219610B (en) | Process for the preparation of new iminodibenzyl derivatives and their salts | |
| DE2933636A1 (en) | NEW N-PHENYLINDOL DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS | |
| DE1518504A1 (en) | Production of substituted phenones | |
| DE3144235A1 (en) | Process for the preparation of 1-(trialkoxybenzyl)- piperazines | |
| CH615422A5 (en) | ||
| AT219609B (en) | Process for the preparation of new iminodibenzyl derivatives and their salts | |
| AT366059B (en) | METHOD FOR PRODUCING NEW PHOSPHONIUM IMIDAZOLE COMPOUNDS AND THEIR ACID ADDITION SALTS | |
| AT387572B (en) | Process for the preparation of novel 4-(4,4-bis(p- fluorophenyl)butyl)-1-carbophenoxypiperazines and of 1- piperazinecarboxamides | |
| AT220619B (en) | Process for the preparation of aminoalkyl benzhydryl ethers | |
| AT270619B (en) | Process for the preparation of new 3,4,5-trimethoxy-β-aminoacrylophenones | |
| AT222104B (en) | Process for the preparation of new cyclobutane derivatives | |
| AT308754B (en) | Process for the preparation of benzodiazepine derivatives and acid addition salts thereof | |
| AT269149B (en) | Process for the preparation of new basic substituted oximes of 6,11-dihydro-dibenz- [b, e] -oxepin- or -thiepin-11-ones and their salts | |
| AT241463B (en) | Process for the preparation of new dibenzocycloheptane derivatives | |
| CH605617A5 (en) | 2-Aminobenzylamine derivs prepn. | |
| DE951630C (en) | Process for the preparation of 22-tertiary-aminobisnorcholanes unsaturated in the 20 (22) position | |
| AT230895B (en) | Process for the preparation of new 6, 11-dihydrodibenzo- [b, e] -thiazepine- [1, 4] derivatives | |
| AT219036B (en) | Process for the preparation of new 3-substituted 1-benzylindanes and their salts | |
| AT233019B (en) | Process for the preparation of new iminodibenzyl derivatives | |
| AT250325B (en) | Process for the production of new unsaturated bases and their salts | |
| AT233579B (en) | Process for the preparation of new iminodibenzyl derivatives | |
| AT219611B (en) | Process for the preparation of new N-heterocyclic compounds and their salts | |
| AT254192B (en) | Process for the production of new quinazolines substituted in the 4-position and their acid addition salts | |
| AT260914B (en) | Process for the preparation of new α- (aminoalkoxyphenyl) -α'-nitrostilbenes and their acid addition salts or quaternary ammonium compounds |